{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:54:12Z","timestamp":1781754852467,"version":"3.54.5"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01795-x","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:49:14Z","timestamp":1779378554000},"page":"3285-3294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and safety of tralokinumab in moderate-to-severe atopic dermatitis with malignancy, chronic infections, and multimorbidity"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-6727","authenticated-orcid":false,"given":"Francisco Javier","family":"Melgosa Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mercader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Santos Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalia","family":"Dominguez Liron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bernabeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Rodriguez Serna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Fernandez-Crehuet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Francisco","family":"Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"4","key":"1795_CR1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40257-025-00931-1","volume":"26","author":"R Chovatiya","year":"2025","unstructured":"Chovatiya R, Ribero S, Wollenberg A, Park CO, Silvestre JF, Hong HC, et al. Long-term disease control and minimal disease activity of head and neck atopic dermatitis in patients treated with Tralokinumab up to 4 years. Am J Clin Dermatol. 2025;26(4):587\u2013601.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1795_CR2","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/jdv.18922","volume":"37","author":"DN Adam","year":"2023","unstructured":"Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol. 2023;37(6):1135\u201348.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1795_CR3","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/jdv.20639","volume":"39","author":"A Wollenberg","year":"2025","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, et al. European guideline (EuroGuiDerm) on atopic eczema: living update. J Eur Acad Dermatol Venereol. 2025;39(9):1537\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1795_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40266-020-00750-5","volume":"37","author":"R Tanei","year":"2020","unstructured":"Tanei R. Atopic dermatitis in older adults: a review of treatment options. Drugs Aging. 2020;37(3):149\u201360.","journal-title":"Drugs Aging"},{"issue":"1","key":"1795_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/derm.2025.0129","volume":"37","author":"G Lauletta","year":"2026","unstructured":"Lauletta G, Potestio L, Patruno C, Ferrucci SM, Angileri L, Barei F, et al. Letter:effectiveness and safety of tralokinumab for the elderly with atopic dermatitis in a real-world setting-IL AD. Dermatitis. 2026;37(1):134\u20139.","journal-title":"Dermatitis"},{"issue":"3","key":"1795_CR6","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3390\/jcm15031117","volume":"15","author":"E Sato","year":"2026","unstructured":"Sato E, Obonai N, Koga M, Sibayama Y, Imafuku S. Older patients with atopic dermatitis show more pronounced early clinical improvement with Tralokinumab: a single-center retrospective real-world study. J Clin Med. 2026;15(3):1117.","journal-title":"J Clin Med"},{"issue":"5","key":"1795_CR7","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s13555-025-01405-2","volume":"15","author":"FJ Melgosa Ramos","year":"2025","unstructured":"Melgosa Ramos FJ, Alarc\u00f3n SS, Motilla JMS, Mercader P. Long-term efficacy and potential predictors of Tralokinumab dose optimization in elderly patients: a multicentre study. Dermatol Ther (Heidelb). 2025;15(5):1251\u20137.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1795_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2147\/JAA.S474411","volume":"17","author":"L Potestio","year":"2024","unstructured":"Potestio L, Patruno C, Dastoli S, Brescia C, Napolitano M. Tralokinumab for the treatment of adult atopic dermatitis in special populations. J Asthma Allergy. 2024;17:791\u20139.","journal-title":"J Asthma Allergy"},{"issue":"2","key":"1795_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/14712598.2026.2628688","volume":"26","author":"E Ippoliti","year":"2026","unstructured":"Ippoliti E, Boeti L, D\u2019Amore A, Cannizzaro MV, Peris K, Gori N. IL-4\/IL-13 targeted biologics in atopic dermatitis: is their use safe in oncologic patients? Expert Opin Biol Ther. 2026;26(2):99\u2013101.","journal-title":"Expert Opin Biol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01795-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01795-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01795-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:23:39Z","timestamp":1781753019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01795-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1795"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01795-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"26 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francisco Javier Melgosa Ramos has received honoraria and\/or travel grants and has served as an advisory board member for Novartis, AbbVie, Janssen-Cilag, UCB, Lilly, LEO Pharma, L\u2019Or\u00e9al, Sanofi, Almirall, and Amgen. Pedro Mercader has received honoraria and\/or travel grants and has served as an advisory board member for Sanofi, LEO Pharma, Lilly, Almirall, and AbbVie. Sergio Santos Alarc\u00f3n has received honoraria and\/or travel grants and has served as an advisory board member for Almirall, AbbVie, Adium Pharma, Amgen, Pfizer, Novartis, Janssen-Cilag, Lilly, LEO Pharma, UCB Pharma, Pierre Fabre, ISDIN, Sanofi, and Vi\u00f1as. Andrea Bernabeu has received honoraria and\/or travel grants and has served as an advisory board member for LEO Pharma. Nalia Dom\u00ednguez Lir\u00f3n, Mercedes Rodr\u00edguez, and Pablo Fern\u00e1ndez-Crehuet declare no conflicts of interest related to this manuscript. Juan Francisco Silvestre Salvador has served as a speaker, advisory board member, and\/or investigator for AbbVie, Almirall, Amgen, Apogee Therapeutics, AstraZeneca, Bristol Myers Squibb, Celldex, Eli Lilly, Galderma, Incyte, LEO Pharma, Nektar Therapeutics, Novartis, Pfizer, Regeneron, and Sanofi Genzyme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was reviewed in accordance with institutional ethics policies and was considered exempt from formal approval in accordance with Spanish Law 14\/2007 on Biomedical Research and EU General Data Protection Regulation (GDPR) 2016\/679 and conducted in accordance with the Declaration of Helsinki, due to its retrospective design and the use of fully anonymized data. In accordance with institutional policies, the requirement for written informed consent was waived. Patients were informed through institutional privacy notices and had the opportunity to opt out of the use of their anonymized data for research purposes. Data were collected and processed in compliance with GDPR standards, and no identifiable personal information was accessible to the investigators. When required, specific consent for publication was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}